Azitra (AZTR) Stock Price, News & Analysis

Company Overview

Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.

The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance. By delivering live commensal organisms directly to affected skin regions, Azitra seeks to restore healthy barrier function and reduce inflammation without relying on conventional small-molecule or biologic drug approaches.

Founded in 2018, Azitra is traded on the NYSE American under the symbol AZTR. Its research and development operations combine microbiology, formulation science and translational dermatology, and the company’s clinical trials are conducted primarily in North America. Azitra has pursued collaborations with academic and medical centers to support its pipeline advancement.

Azitra’s leadership team brings together expertise in microbiome research, dermatology and pharmaceutical development, guiding the company toward regulatory milestones and strategic partnerships. With a mission to harness the therapeutic potential of the skin microbiome, Azitra aims to offer novel, targeted treatments for patients with chronic skin diseases.

Key Stats

• Today's Range: $0.24 to $0.26
• 50-Day Range: $0.14 to $0.30
• 52-Week Range: $0.10 to $2.40
• Volume: 351,754 shs
• Average Volume: 9.23 million shs
• Market Capitalization: $4.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Buy

Azitra Stock Analysis - MarketRank™

Azitra scored higher than 55% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Azitra has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Azitra has a consensus price target of $4.00, representing about 1,481.0% upside from its current price of $0.25.

Amount of Analyst Coverage

Azitra has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Azitra are expected to grow in the coming year, from ($0.71) to ($0.55) per share.

Price to Book Value per Share Ratio

Azitra has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.44% of the float of Azitra has been sold short.

Short Interest Ratio / Days to Cover

Azitra has a short interest ratio ("days to cover") of 0.68, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Azitra has recently decreased by 77.11%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Azitra does not currently pay a dividend.

Dividend Growth

Azitra does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Azitra this week, compared to 1 article on an average week.

Search Interest

Only 5 people have searched for AZTR on MarketBeat in the last 30 days. This is a decrease of -74% compared to the previous 30 days.

MarketBeat Follows

12 people have added Azitra to their MarketBeat watchlist in the last 30 days. This is an increase of 1,100% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Azitra insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.10% of the stock of Azitra is held by insiders.

Percentage Held by Institutions

11.16% of the stock of Azitra is held by institutions.

AZTR Stock Analysis - Frequently Asked Questions

How have AZTR shares performed this year?

Azitra's stock was trading at $0.2648 on January 1st, 2026. Since then, AZTR shares have decreased by 4.5% and is now trading at $0.2530.

How were Azitra's earnings last quarter?

Azitra, Inc. (NYSEAMERICAN:AZTR) announced its quarterly earnings results on Wednesday, November, 12th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.79) by $0.12.

When did Azitra's stock split?

Shares of Azitra reverse split before market open on Friday, August 22nd 2025.The 100-666 reverse split was announced on Monday, August 11th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 21st 2025. An investor that had 100 shares of stock prior to the reverse split would have 15 shares after the split.

How do I buy shares of Azitra?

Shares of AZTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Azitra own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Azitra investors own include NVIDIA (NVDA), Broadcom (AVGO), Tesla (TSLA), Advanced Micro Devices (AMD), CrowdStrike (CRWD), FedEx (FDX) and Intel (INTC).

Company Calendar

• Last Earnings: 11/12/2025
• Today: 5/06/2026
• Next Earnings (Estimated): 5/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:AZTR
• CIK: 1701478
• Web: azitrainc.com
• Phone: 203-646-6446
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Azitra: $4.00
• High Price Target: $4.00
• Low Price Target: $4.00
• Potential Upside/Downside: +1,519.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.95 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -344.58%
• Return on Assets: -228.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.83
• Quick Ratio: 2.83

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 399.89
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.35 per share
• Price / Book: 0.71

Miscellaneous

• Outstanding Shares: 16,190,000
• Free Float: 16,176,000
• Market Cap: $4.00 million
• Optionable: Not Optionable
• Beta: -1.40